D060828

4 trials

Sponsors

Watanabe Akinori, Tate Shinichi, Muramatsu Hideki, Goto Hiroaki

Conditions

CD19-positive B cell precursor acute lymphoblastic leukemia children, relapsed, refractory, acute lymphoblastic leukemiaProblem(s) Studied Esophageal squamous cell carcinomaTransient abnormal myelopoiesis Leukemia, Transient, Down syndromeovarian cancer ovarian cancer

Phase 1

Weekly liposomal doxorubicin and cisplatin chemotherapy for patients with ovarian cancer, phase I study

Active, not recruitingJPRN-jRCTs031200007

Tate Shinichiovarian cancer ovarian cancer

Start: 2020-06-03Target: 24Updated: 2025-07-18

Phase 2

Chemoselection as a strategy for organ preservation in clinical stage II/III ESCC: a phase II study of induction chemotherapy with docetaxel, cisplatin and 5-FU (DCF) followed by chemoradiotherapy.

Active, not recruitingJPRN-jRCTs031180380

Watanabe AkinoriProblem(s) Studied Esophageal squamous cell carcinoma

Start: 2012-07-05Target: 100Updated: 2025-07-18

Phase II clinical trials aiming to establish standard therapy by chemotherapy for transient myelodysplastic syndrome (TAM)

RecruitingJPRN-jRCTs041190063

Muramatsu HidekiTransient abnormal myelopoiesis Leukemia, Transient, Down syndrome

Start: 2019-09-30Target: 250Updated: 2025-07-18

The novel induction therapy by low-dose cytarabine and blinatumomab for relapse/refractory ALL

Active, not recruitingJPRN-jRCTs041210107

Goto HiroakiCD19-positive B cell precursor acute lymphoblastic leukemia children, relapsed, refractory, acute lymphoblastic leukemia

Start: 2022-01-28Target: 45Updated: 2025-07-18

Related Papers

Cytokine profiling in 128 patients with transient abnormal myelopoiesis: a report from the JPLSG TAM-10 trial

Blood Advances2024-05-011 citations